Yıl: 2021 Cilt: 22 Sayı: 4 Sayfa Aralığı: 293 - 299 Metin Dili: İngilizce DOI: 10.4274/jtgga.galenos.2020.2020.0110 İndeks Tarihi: 20-01-2022

The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation

Öz:
Objective: Progestins are used as an alternative to gonadotropin releasing hormone (GnRH) antagonists to suppress premature luteinizing hormone (LH) surge and a flexible protocol has been defined recently. The aim of this study was to compare the efficacy of flexible protocols with dydrogesterone and GnRH antagonist in suppressing LH surge. Material and Methods: This retrospective, case-control study, was conducted in an infertility unit of a tertiary university hospital. A daily dose of 40 mg dydrogesterone was compared with GnRH antagonist (GnRHant) in controlled ovarian hyperstimulation cycles between July 2018 and July 2019. Dydrogesterone was started when the leading follicle was 12 mm or serum estradiol was over 300 pg/mL. A subgroup analysis of poor responder patients was also performed. Results: In total there were 105 subjects aged between 23 and 41 years, 52 in the dydrogesterone group and 53 in the GnRHant group. Duration of pituitary suppression was longer in dydrogesterone group. Premature ovulation was observed in 11.5% (6/52) and 0% in the dydrogesterone and GnRHant groups, respectively. However, collected oocyte counts and metaphase II oocyte counts were found to be similar between the groups. The six patients with premature ovulation were in poor responder subgroup. Conclusion: Dydrogesterone can be used as an alternative to antagonist regimen in patients where embryo transfer is not planned in the same cycle. However, flexible regimen may not be appropriate in patients with diminished ovarian reserve, as advanced follicular maturation and delayed suppressive effect of oral progesterone may cause premature ovulation. Randomized controlled trials in particular patient groups are required to determine the most effective minimum dose and time of application to ensure treatment success. (J Turk Ger Gynecol Assoc 2021; 22: 293-9)
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 2015; 104: 62-70.
  • 2. Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update 2017; 23: 211-20.
  • 3. Wang Y, Kuang Y, Chen Q, Cai R. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial. Trials 2018; 19: 455.
  • 4. Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod 2018; 33: 229-37.
  • 5. Chen YM, Qi QR, Xie QZ, Yang YF, Xia Y, Zhou XD. Effect of progestinprimed ovarian stimulation protocol on outcomes of aged infertile women who failed to get pregnant in the first IVF/ ICSI Cycle: A self-controlled study. Curr Med Sci 2018; 38: 513-8.
  • 6. Cobo A, Kuwayama M, Pérez S, Ruiz A, Pellicer A, Remohí J. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. Fertil Steril 2008; 89: 1657-64.
  • 7. Xiao ZN, Peng JL, Yang J, Xu WM. Flexible GnRH antagonist protocol versus progestin-primed ovarian stimulation (PPOS) protocol in patients with polycystic ovary syndrome: comparison of clinical outcomes and ovarian response. Curr Med Sci 2019; 39: 431-6.
  • 8. Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X, et al. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Front Endocrinol 2019; 10: 796.
  • 9. Yildiz S, Turkgeldi E, Angun B, Eraslan A, Urman B, Ata B. Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertil Steril 2019; 112: 677-83.
  • 10. Grisendi V, Mastellari E, La Marca A. Ovarian reserve markers to identify poor responders in the context of poseidon classification. Front Endocrinol 2019; 10: 281.
  • 11. Inaudi P, Barra V, Vellucci FL, Regini C, Luisi S. GnRH antagonist does not prevent premature luteinization and ovulation in stimulated cycles with gonadotropins for IVF: two case reports. Gynecol Endocrinol 2018; 34: 189-91.
  • 12. Attardi B, Scott R, Pfaff D, Fink G. Facilitation or inhibition of the oestradiol-induced gonadotrophin surge in the immature female rat by progesterone: effects on pituitary responsiveness to gonadotrophin-releasing hormone (GnRH), GnRH self-priming and pituitary mRNAs for the progesterone receptor A and B isoforms. J Neuroendocrinol 2007; 19: 988-1000.
  • 13. Evans MB, Parikh T, DeCherney AH, Csokmay JM, Healy MW, Hill MJ. Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles. Reprod Biomed Online 2019; 38: 691-8.
  • 14. Beguería R, García D, Vassena R, Rodríguez A. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod 2019; 34: 872-80.
  • 15. Ata B, Capuzzo M, Turkgeldi E, Yildiz S, La Marca A. Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses. Hum Reprod Update 2021; 27: 48-66.
  • 16. Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in Patients with polycystic ovary syndrome treated for IVF: a doubleblind randomized crossover clinical trial. Medicine 2016; 95: e2939.
  • 17. Huang P, Tang M, Qin A. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ ICSI compared to a GnRH antagonist protocol: A retrospective study. J Gynecol Obstet Hum Reprod 2019; 48: 99-102.
  • 18. Turkgeldi E, Yildiz S, Cekic SG, Shakerian B, Keles I, Ata B. Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve. Hum Fertil 2020: 1-7.
  • 19. Wikström A, Green B, Johansson ED. The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses. Acta Obstet Gynecol Scand 1984; 63: 163-8.
  • 20. Dong J, Wang Y, Chai WR, Hong QQ, Wang NL, Sun LH, et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG 2017; 124: 1048-55.
  • 21. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas 2008; 61: 171-80.
  • 22. Rižner TL, Brožič P, Doucette C, Turek-Etienne T, Müller-Vieira U, Sonneveld E, et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids 2011; 76: 607-15.
  • 23. Bosch E, Valencia I, Escudero E, Crespo J, Simon C, Remohí J, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril 2003; 80: 1444-9.
  • 24. Reichman DE, Zakarin L, Chao K, Meyer L, Davis OK, Rosenwaks Z. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertil Steril 2014; 102: 99-102.
  • 25. Lu X, Hong Q, Sun L, Chen Q, Fu Y, Ai A, et al. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. Fertil Steril 2016; 106: 1356-62.
  • 26. Helmond F, Simons P, Hein P. The effects of progesterone on estrogen-induced luteinizing hormone and follicle-stimulating hormone release in the female rhesus monkey. Endocrinology 1980; 107: 478-85.
  • 27. Helmond FA, Simons PA, Hein PR. Strength and duration characteristics of the facilitory and inhibitory effects of progesterone on the estrogen-induced gonadotropin surge in the female rhesus monkey. Endocrinology 1981; 108: 1837-42.
  • 28. Klein NA, Harper AJ, Houmard BS, Sluss PM, Soules MR. Is the short follicular phase in older women secondary to advanced or accelerated dominant follicle development? J Clin Endocrinol Metab 2002; 87: 5746-50.
  • 29. Luborsky J, Thiruppathi P, Rivnay B, Roussev R, Coulam C, Radwanska E. Evidence for different aetiologies of low estradiol response to FSH: age-related accelerated luteinization of follicles or presence of ovarian autoantibodies. Hum Reprod 2002; 17: 2641- 9.
  • 30. Wu FS, Lee RK, Hwu YM. Encountering premature ovulation during controlled ovarian hyperstimulation in IVF/ICSI cycles. Taiwan J Obstet Gynecol 2012; 51: 256-9.
APA Doğan Durdağ G, bektas g, türkyılmaz e, Göktepe H, Sonmezer M, Şükür Y, Ozmen B, Atabekoğlu C, Berker B, Aytac R, Sönmezer M (2021). The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. , 293 - 299. 10.4274/jtgga.galenos.2020.2020.0110
Chicago Doğan Durdağ Gülşen,bektas gizem,türkyılmaz esengül,Göktepe Halime,Sonmezer Meltem,Şükür Yavuz Emre,Ozmen Batuhan,Atabekoğlu Cem Somer,Berker Bülent,Aytac Rusen,Sönmezer Murat The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. (2021): 293 - 299. 10.4274/jtgga.galenos.2020.2020.0110
MLA Doğan Durdağ Gülşen,bektas gizem,türkyılmaz esengül,Göktepe Halime,Sonmezer Meltem,Şükür Yavuz Emre,Ozmen Batuhan,Atabekoğlu Cem Somer,Berker Bülent,Aytac Rusen,Sönmezer Murat The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. , 2021, ss.293 - 299. 10.4274/jtgga.galenos.2020.2020.0110
AMA Doğan Durdağ G,bektas g,türkyılmaz e,Göktepe H,Sonmezer M,Şükür Y,Ozmen B,Atabekoğlu C,Berker B,Aytac R,Sönmezer M The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. . 2021; 293 - 299. 10.4274/jtgga.galenos.2020.2020.0110
Vancouver Doğan Durdağ G,bektas g,türkyılmaz e,Göktepe H,Sonmezer M,Şükür Y,Ozmen B,Atabekoğlu C,Berker B,Aytac R,Sönmezer M The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. . 2021; 293 - 299. 10.4274/jtgga.galenos.2020.2020.0110
IEEE Doğan Durdağ G,bektas g,türkyılmaz e,Göktepe H,Sonmezer M,Şükür Y,Ozmen B,Atabekoğlu C,Berker B,Aytac R,Sönmezer M "The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation." , ss.293 - 299, 2021. 10.4274/jtgga.galenos.2020.2020.0110
ISNAD Doğan Durdağ, Gülşen vd. "The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation". (2021), 293-299. https://doi.org/10.4274/jtgga.galenos.2020.2020.0110
APA Doğan Durdağ G, bektas g, türkyılmaz e, Göktepe H, Sonmezer M, Şükür Y, Ozmen B, Atabekoğlu C, Berker B, Aytac R, Sönmezer M (2021). The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. Journal of the Turkish-German Gynecological Association, 22(4), 293 - 299. 10.4274/jtgga.galenos.2020.2020.0110
Chicago Doğan Durdağ Gülşen,bektas gizem,türkyılmaz esengül,Göktepe Halime,Sonmezer Meltem,Şükür Yavuz Emre,Ozmen Batuhan,Atabekoğlu Cem Somer,Berker Bülent,Aytac Rusen,Sönmezer Murat The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. Journal of the Turkish-German Gynecological Association 22, no.4 (2021): 293 - 299. 10.4274/jtgga.galenos.2020.2020.0110
MLA Doğan Durdağ Gülşen,bektas gizem,türkyılmaz esengül,Göktepe Halime,Sonmezer Meltem,Şükür Yavuz Emre,Ozmen Batuhan,Atabekoğlu Cem Somer,Berker Bülent,Aytac Rusen,Sönmezer Murat The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. Journal of the Turkish-German Gynecological Association, vol.22, no.4, 2021, ss.293 - 299. 10.4274/jtgga.galenos.2020.2020.0110
AMA Doğan Durdağ G,bektas g,türkyılmaz e,Göktepe H,Sonmezer M,Şükür Y,Ozmen B,Atabekoğlu C,Berker B,Aytac R,Sönmezer M The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. Journal of the Turkish-German Gynecological Association. 2021; 22(4): 293 - 299. 10.4274/jtgga.galenos.2020.2020.0110
Vancouver Doğan Durdağ G,bektas g,türkyılmaz e,Göktepe H,Sonmezer M,Şükür Y,Ozmen B,Atabekoğlu C,Berker B,Aytac R,Sönmezer M The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. Journal of the Turkish-German Gynecological Association. 2021; 22(4): 293 - 299. 10.4274/jtgga.galenos.2020.2020.0110
IEEE Doğan Durdağ G,bektas g,türkyılmaz e,Göktepe H,Sonmezer M,Şükür Y,Ozmen B,Atabekoğlu C,Berker B,Aytac R,Sönmezer M "The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation." Journal of the Turkish-German Gynecological Association, 22, ss.293 - 299, 2021. 10.4274/jtgga.galenos.2020.2020.0110
ISNAD Doğan Durdağ, Gülşen vd. "The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation". Journal of the Turkish-German Gynecological Association 22/4 (2021), 293-299. https://doi.org/10.4274/jtgga.galenos.2020.2020.0110